It takes real-world data to drive breakthroughs with real impact. Significantly enhance you process management using neurological data nQ Medical.
With real data, anything is possible.
nQ Medical’s artificial intelligence-powered computational biomarker yields powerful insights. We believe that the way our fingers interact with computers can reveal the presence of certain neuromotor and neurocognition diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis.
The fine control of typing and touch screen kinematics, as well as the frequent use of personal devices like smart phones brings real world data to clinicians.
Breakthrough Innovation in Clinical Trials | 2019
nQ Medical is pleased to be honored with the D4 INNOVATION AWARD recognizing the most innovative breakthrough technology affecting data-driven drug development. Read the Frontline Genomics article here
Top eClinical Trial Solution
Provider | 2019
nQ Medical is please to be recognized by a distinguished selection panel of CEOs,CIOs, VCs, Industry Analysts, and PharmaTech Outlook’s Editorial Board as one of the Top 10 eClinical Trial solution providers in 2019.
PRISME Forum | 2017
nQ Medical is pleased to be named a Top AI Start-Up by the PRISME Forum in 2017. Awards and accolades don’t drive us, but it’s nice to be recognized. Read the Business Insider article here.
nQ Medical magazine ad | 2019
Recent advances in technology are opening new opportunities to remotely evaluate motor features in people with Parkinson’s. This study showed that using nQ to monitor typing, a habitual behavior facilitated by the nigrostriatal dopaminergic pathway, could allow for objectively and non-obtrusively monitoring Parkinsonian features and response to medication in an at‐home setting. Read the paper here.
This publication is on the value of nQ as a remote monitoring tool for Parkinson’s. The paper compares nQ’s performance in-clinic and at-home and showed that it provides similar quality measurements as a traditional in-clinic evaluation. Read the paper here.
In this study nQ presented our first result from the analysis of data gathered using smartphones. We showed that we can accurately discriminate an early PD population with mild Parkinsonian signs from a healthy control group by comparing the typing patterns from their interaction with touchscreen keyboards. Read the paper here.
In nQ’s first study focused on Parkinson’s Disease, we showed data indicating that the routine interaction with computer keyboards can be used to detect motor signs in the early stages of Parkinson’s. We presented a solution that relies on keystroke data from daily use of personal computers and converts it into a PD motor index. Read the paper here.
In this proof of concept study, nQ demonstrated that daily interaction with a computer keyboard can be employed as means to observe and potentially quantify psychomotor impairment. This initial work in sleep inertia demonstrates that clinically relevant motor function changes can be measured by timing key press/release events from a typing routine on a physical keyboard, irrespective of the language or the typed text. Read the paper here.
CEO & Founder
Founder & Executive Chairman
Teresa Arroyo Gallego PhD
Chief Data Scientist
Rahul Mahajan , MD
Chief Medical Officer
Ijah Mondesire-Crump, MD
Director, Clinical Research
Naomi Fried, PhD
CEO, Health Innovation Strategies
Maulik Majmudar, MD
Chief Medical Officer, Health & Wellness, Amazon
David Lee Scher, MD
Cardiologist, Digital Health Consultant
John Baldoni, PhD
SVP, R&D, GSK
David Kreutter, PhD
Pfizer, Kreutter Life Sciences LLC
Zoltan Mari, MD
Chief, Movement Disorder Program, The Cleveland Clinic, Lou Ruvo Center for Brain Health